Holen Sie sich die Stockscreener-App
916.69
1.12%
9.99
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Here's How Much Upside Eli Lilly Stock Has, According to Analysts - Yahoo Finance
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
AI Models Split on Eli Lilly: Growth Strength vs. Premium Valuation - TipRanks
Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs - GlobeNewswire Inc.
Lehigh Valley planners to discuss traffic, other potential issues with proposed Eli Lilly plant - The Morning Call
Procyon Advisors LLC Has $7.77 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's diabetes drug cuts weight by 17% in trial - qz.com
Aventura Private Wealth LLC Buys Shares of 3,861 Eli Lilly and Company $LLY - MarketBeat
GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug - The Daily Upside
Eli Lilly Bets Billions on Asian Expansion with Major China Push - AD HOC NEWS
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Insider Monkey
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
Eli Lilly (LLY) Downgraded by HSBC Amid Valuation Concerns - GuruFocus
Eli Lilly and Co. shares update on LEAP construction, workforce development - Inside INdiana Business
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
Should You Buy Eli Lilly Stock Before April 10? - The Motley Fool
Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly
Sagespring Wealth Partners LLC Has $10.59 Million Stake in Eli Lilly and Company $LLY - MarketBeat
The stock prices of Eli Lilly and Novo Nordisk, which have divided the global obesity treatment mark.. - 매일경제
Eli Lilly's Market Outlook: Weight Loss Drugs, Competition, and Portfolio DiversificationNews and Statistics - IndexBox
India is well positioned to attract future investments: Patrick Johnson, President, Lilly International - The Economic Times
India is well positioned to attract future investments, says Eli Lilly's Patrick Johnson - The Economic Times
Eli Lilly & Co Slides as Bold Pipeline Tested - TipRanks
Is Eli Lilly (LLY) Still Attractive After Its Multi Year Share Price Surge - simplywall.st
AI Models Split on Eli Lilly (LLY) as Growth Story Meets Rich Valuation - TipRanks
Union Bancaire Privee UBP SA Sells 3,199 Shares of Eli Lilly and Company $LLY - MarketBeat
BMO Capital Remains a Buy on Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly and Company $LLY Shares Purchased by Neville Rodie & Shaw Inc. - MarketBeat
Park Avenue Securities LLC Acquires 2,711 Shares of Eli Lilly and Company $LLY - MarketBeat
Coastline Trust Co Boosts Stake in Eli Lilly and Company - National Today
Coastline Trust Co Has $21.74 Million Position in Eli Lilly and Company $LLY - MarketBeat
GAMMA Investing LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Anderson Hoagland & Co. Has $22.12 Million Position in Eli Lilly and Company $LLY - MarketBeat
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment - Investing.com
Eli Lilly and Company $LLY Shares Bought by AIA Group Ltd - MarketBeat
China Commerce Minister Hopes Lilly Will Deepen China Commitment - Bloomberg.com
Eli Lilly Beats 9th Circ. Appeal Over Brain Bleed After Cialis - Law360
ELI LILLY & Co ($LLY) CEO 2025 Pay Revealed - Quiver Quantitative
Eli Lilly and Company (NYSE:LLY) Shares Down 1.3%What's Next? - MarketBeat
Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial - Insider Monkey
Eli Lilly (NYSE: LLY) 2026 proxy outlines pay, performance and governance votes - Stock Titan
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Eli Lilly & Co. stock faces pressure amid pipeline setbacks and GLP-1 competition - AD HOC NEWS
Scotiabank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why Eli Lilly Remains My Top Obesity Bet (NYSE:LLY) - Seeking Alpha
Jim Cramer says "Buy Eli Lilly" - MSN
Jim Cramer Says “Buy Eli Lilly” - Insider Monkey
Lilly-partnered Fauna announces designation of novel obesity target - The Pharma Letter
Eli Lilly stock price forecast for 2040: Drug innovation pipeline supports long-term outlook towards $2,500 - Traders Union
Eli Lilly (LLY) Faces Reevaluation of Alzheimer's Drug Decision - GuruFocus
Lilly’s manufacturing bet; hints of a biotech revival - Pharma Voice
Long Acting Injectables Market Is Going to Boom |Eli Lilly - openPR.com
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,500 - 富途牛牛
Eli Lilly (LLY) and Biogen (BIIB) Alzheimer's Drug Review by UK Watchdog - GuruFocus
Swiss Life Asset Management Ltd Raises Stock Position in Eli Lilly and Company $LLY - MarketBeat
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern - Yahoo! Finance Canada
Mirova Decreases Stake in Eli Lilly and Company $LLY - MarketBeat
Mainstay Capital Management LLC ADV Has $1.17 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
England to Review Rejection of Alzheimer’s Drugs for NHS - Bloomberg.com
Allworth Financial LP Acquires 5,249 Shares of Eli Lilly and Company $LLY - MarketBeat
LLY Stock Price, Quote & Chart | ELI LILLY & CO (NYSE:LLY) - ChartMill
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results - Insider Monkey
England to Review Rejection of Eli Lilly Alzheimer’s Drug for NHS - Bloomberg.com
Lilly’s experimental diabetes shot yields record weight loss in study - UnionLeader.com
Triple crown: T2D purse for Lilly’s phase III retatrutide? - BioWorld MedTech
Leerink reiterates Eli Lilly stock rating on diabetes drug data - Investing.com
0.16%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):